Axonics

Axonics Debt/EBITDA

Total Debt to EBITDA Ratio of Axonics (AXNX) as of Nov 19, 2026.

Debt/EBITDA

0.00

Last updated:

Total Debt to EBITDA Ratio of Axonics is 2023 0.00 . Total Debt to EBITDA Ratio of Axonics was 2022 0.00 . It decreases by % lower compared to the previous year.

The Axonics Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2016
-0.02 USD
Jan 1, 2017
-0.01 USD
Jan 1, 2018
-0.73 USD
Jan 1, 2019
-0.25 USD
Jan 1, 2020
-0.39 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
0.00 USD
The Axonics Debt/EBITDA history
YEARDebt/EBITDAYoY
0.00—
0.00—
0.00-100.00%
-0.39+55.31%
-0.25-65.56%
-0.73+13,189.87%
-0.01-67.93%
-0.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Axonics Stock analysis

What does Axonics do? Axonics Modulation Technologies Inc. is a medical device company that was founded in 2013 and is headquartered in Irvine, California. The company specializes in the development and marketing of innovative therapy devices for the treatment of bladder dysfunction and bowel diseases. Axonics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Axonics stock

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Axonics since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Axonics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Axonics

All Key Metrics — Axonics